Hydrogel cross-linked hyaluronic acid prodrug compositions and methods

US12246070B2 · kind B2 · utility

Assignee

• ASCENDIS PHARMA A/S · DK

Inventors

• Sebastian Stark · Heidelberg, DE
• Thomas Knappe · Heidelberg, DE
• Harald Rau · Würzburg, DE
• Nicola Bisek · Heidelberg, DE
• Burkhardt Laufer · Birkenfeld, DE
• Samuel Weisbrod · Heidelberg, DE
• Tobias Voigt · Heidelberg, DE

Key dates

• Filing date: Mar 27, 2023
• Grant date: Mar 11, 2025
• Expiry date: Mar 27, 2043

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P27/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.